Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil E Kay

Showing results (101-110 of 325) with videos related to

Pageof 33
Sort By:
Translational Research : the Journal of Laboratory and Clinical Medicine|March 27, 2007
Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemiaWilliam Martin, Roshini Abraham, Tait Shanafelt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2015
Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK InhibitorsSutapa Sinha, Justin Boysen, Michael Nelson, et al.
British Journal of Haematology|June 6, 2017
Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort studyPaolo Strati, Sameer A Parikh, Kari G Chaffee, et al.
Cancer|May 22, 2007
Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemiaTait D Shanafelt, Thomas Lin, Susan M Geyer, et al.
British Journal of Haematology|November 21, 2007
Susceptibility genes and B-chronic lymphocytic leukaemiaSusan L Slager, Neil E Kay, Zachary S Fredericksen, et al.
Leukemia & Lymphoma|August 3, 2012
Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximabClive S Zent, Wenting Wu, Deborah A Bowen, et al.
Leukemia Research|July 1, 2008
Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximabClive S Zent, Charla R Secreto, Betsy R LaPlant, et al.
Blood|September 25, 2004
Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabineTait D Shanafelt, Yean K Lee, Nancy D Bone, et al.
Cancer|December 18, 2008
Validation of a new prognostic index for patients with chronic lymphocytic leukemiaTait D Shanafelt, Greg Jenkins, Timothy G Call, et al.
Leukemia & Lymphoma|March 23, 2010
Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisoneDeborah A Bowen, Timothy G Call, Tait D Shanafelt, et al.
Pageof 33

Showing results (101-110 of 325) with videos related to

Sort By:
Pageof 33
Translational Research : the Journal of Laboratory and Clinical Medicine|March 27, 2007
Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemiaWilliam Martin, Roshini Abraham, Tait Shanafelt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2015
Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK InhibitorsSutapa Sinha, Justin Boysen, Michael Nelson, et al.
British Journal of Haematology|June 6, 2017
Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort studyPaolo Strati, Sameer A Parikh, Kari G Chaffee, et al.
Cancer|May 22, 2007
Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemiaTait D Shanafelt, Thomas Lin, Susan M Geyer, et al.
British Journal of Haematology|November 21, 2007
Susceptibility genes and B-chronic lymphocytic leukaemiaSusan L Slager, Neil E Kay, Zachary S Fredericksen, et al.
Leukemia & Lymphoma|August 3, 2012
Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximabClive S Zent, Wenting Wu, Deborah A Bowen, et al.
Leukemia Research|July 1, 2008
Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximabClive S Zent, Charla R Secreto, Betsy R LaPlant, et al.
Blood|September 25, 2004
Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabineTait D Shanafelt, Yean K Lee, Nancy D Bone, et al.
Cancer|December 18, 2008
Validation of a new prognostic index for patients with chronic lymphocytic leukemiaTait D Shanafelt, Greg Jenkins, Timothy G Call, et al.
Leukemia & Lymphoma|March 23, 2010
Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisoneDeborah A Bowen, Timothy G Call, Tait D Shanafelt, et al.
Pageof 33